Max Mednik
  • Home
  • About
  • Interests
    • Angel investing
    • Magic
    • Scuba Diving
  • Blog
  • Contact

Readings and musings

Why I invested in Contraline

5/25/2018

0 Comments

 
Picture
I’m really excited to have been able to invest in Contraline. Based in Charlottesville, Virginia, Contraline is a medical device company developing the first long-lasting, non-hormonal, and reversible male contraceptive.

The company was started by a founder (fellow immigrant!) who is passionate about giving men more options and responsibility in contraception. He wrote essays to get into college about the lack of a male birth control pill and has been working tirelessly to recruit a strong team of scientists with an actual lab and tangible progress towards clinical trials. If successful, the product would be game-changing, and I acknowledge the risks are very large and probability of success low. I like that the founder is so committed to seeing his vision turn into reality. I’m proud to have invested alongside Jason Calacanis, Mike Savino, LAUNCH, Founders Fund, FundRx, and Abstract Ventures.

I’m personally excited about the company because the options for men are indeed very limited (either not very effective or permanent and painful). 73% of couples in the world rely on female partners for contraception. I believe the societal and social impact from giving men more options and responsibility would greatly benefit gender relations and couple dynamics overall. And I like that there are defensible scientific advances at the core of this technology that have the chance to be executed upon by a good team.

Couples and physicians can register their interest in Contraline here:
http://www.contraline.com/participate

Here is recent press coverage on the company:
TechCrunch, WMRA

What I love:
  • Immigrant founder maniacal about his vision
  • Built strong scientific team
  • 8 patents filed
  • Actual running operations in a lab, making good progress through milestones
  • Product is differentiated from competition

Risks:
  • Difficult, long, expensive, risky process to get to FDA approval
  • Full product technology value proposition still not entirely proven out
  • Need to get physicians on board to promote and incorporate it into their practices
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    June 2021
    May 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    April 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    May 2019
    March 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    February 2018
    January 2018
    November 2017
    October 2017
    September 2017
    May 2017
    April 2017
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011
    April 2011
    March 2011
    February 2011
    January 2011
    December 2010
    November 2010
    October 2010
    September 2010
    August 2010
    July 2010
    June 2010
    May 2010
    April 2010
    March 2010
    February 2010

    Categories

    All
    Angel Investing
    Cacti
    Cars
    China
    Community Service
    Culture
    Design
    Djing
    Dogs
    Education
    Entertainment
    Entrepreneurship
    Family
    Finance
    Food
    Google
    Happiness
    Incentives
    Investment Banking
    Judaism
    Law
    Lighting
    Magic
    Marketing
    Medicine
    Networking
    Nolabound
    Philosophy
    Professionalism
    Psychology
    Reading
    Real Estate
    Religion
    Romance
    Sales
    Science
    Shangri-La
    Social Entrepreneurship
    Social Media
    Sports
    Teams
    Technology
    Travel
    Turtles
    Ucla
    Venture Capital
    Web Services
    Weddings
    Zen

    Subscribe

    RSS Feed

Picture
Picture
  • Home
  • About
  • Interests
    • Angel investing
    • Magic
    • Scuba Diving
  • Blog
  • Contact